Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma.
Mol Cancer. 2024 Feb 22;23(1):40. doi: 10.1186/s12943-024-01955-7.
Mol Cancer. 2024.
PMID: 38383439
Free PMC article.
The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma.
Feichtenschlager V, Chen L, Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Fewings E, Lee A, Chen C, Callanan C, Lin K, Qu T, Hohlova D, Vujic M, Hwang Y, Lai K, Chen S, Nguyen T, Muñoz DP, Kohwi Y, Posch C, Daud A, Rappersberger K, Kohwi-Shigematsu T, Coppé JP, Ortiz-Urda S.
Feichtenschlager V, et al.
Res Sq [Preprint]. 2023 Dec 1:rs.3.rs-1297358. doi: 10.21203/rs.3.rs-1297358/v3.
Res Sq. 2023.
PMID: 38077055
Free PMC article.
Updated.
Preprint.
Item in Clipboard
Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment.
Feichtenschlager V, Zheng YJ, Ho W, Chen L, Callanan C, Chen C, Lee A, Ortiz J, Rappersberger K, Ortiz-Urda S.
Feichtenschlager V, et al.
Oncotarget. 2023 May 26;14:543-560. doi: 10.18632/oncotarget.28447.
Oncotarget. 2023.
PMID: 37235843
Free PMC article.
Item in Clipboard
Clinical melanoma characteristics and survival-a single-center retrospective study between 2000 and 2010.
Feichtenschlager V, Weihsengruber F, Richter L, Vujic I, Rappersberger K, Posch C.
Feichtenschlager V, et al.
Wien Med Wochenschr. 2019 Oct;169(13-14):323-330. doi: 10.1007/s10354-018-0678-3. Epub 2019 Jan 16.
Wien Med Wochenschr. 2019.
PMID: 30649651
English.
Item in Clipboard
Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.
Vujic I, Posch C, Sanlorenzo M, Yen AJ, Tsumura A, Kwong A, Feichtenschlager V, Lai K, Arneson DV, Rappersberger K, Ortiz-Urda SM.
Vujic I, et al. Among authors: feichtenschlager v.
Oncotarget. 2014 Sep 15;5(17):7936-44. doi: 10.18632/oncotarget.2326.
Oncotarget. 2014.
PMID: 25277205
Free PMC article.
Item in Clipboard
Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients.
Posch C, Weihsengruber F, Bartsch K, Feichtenschlager V, Sanlorenzo M, Vujic I, Monshi B, Ortiz-Urda S, Rappersberger K.
Posch C, et al. Among authors: feichtenschlager v.
Br J Cancer. 2014 Mar 18;110(6):1427-32. doi: 10.1038/bjc.2014.62. Epub 2014 Feb 11.
Br J Cancer. 2014.
PMID: 24518593
Free PMC article.
Item in Clipboard
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S.
Posch C, et al. Among authors: feichtenschlager v.
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4015-20. doi: 10.1073/pnas.1216013110. Epub 2013 Feb 19.
Proc Natl Acad Sci U S A. 2013.
PMID: 23431193
Free PMC article.
Item in Clipboard
Cite
Cite